UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





FORM
10-K





x     Annual
Report Pursuant to Section 13 or 15(d) of the Securities Exchange


Act of
1934





For the
fiscal year ended March 31, 2010





 ̈     Transition
Report under Section 13 of 15(d) of the Securities Exchange


Act of
1934





For the
transition period from ___________ to __________





Commission
file number: 000-53364





CHINA
DOMESTICA BIO-TECHNOLOGY HOLDINGS, INC.





(Exact
Name of Registrant as specified in its charter)





Nevada
              
              20-5432794(State or other jurisdiction of
              
              (I.R.S. Employerincorporation or organization)
              
              Identification No.)





Room 2303, 2304 ShenFang Square, 3005 RenMing
                  Road South, LuFung District, Shenzhen, China
                
                518001(Address of principal executive offices)
                
                (Zip code)





Registrant’s
telephone number, including area code: (86) 13168096855





Securities
registered under Section 12(b) of the Exchange Act:





None





Securities
registered under Section 12(g) of the Exchange Act:





Common
Stock, $.001 par value





Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act.  Yes  ̈  No
x





Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 of Section 15(d) of the Act.  Yes  ̈  No
x





Indicate
by check mark whether the Registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the Registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes o No x





Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of
this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes  ̈ No
 ̈





Indicate
by check mark if disclosure of delinquent filers pursuant to item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.  ̈





Indicate
by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting
company:





Large accelerated filer
             ̈
            Accelerated filer
             ̈Non-accelerated filer
             ̈
            Smaller reporting company
            x





Indicate
by check mark whether the Registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).  Yes x No
 ̈





The
aggregate market value of the Registrant's voting and non-voting common equity
held by non-affiliates of the Registrant was approximately $134,558 at September
30, 2009, computed at the last reported sales price as of such date for the
Registrant's common stock of $0.15.





As of
August 5, 2010, the registrant had 49,896 shares of common stock outstanding
(giving effect to the 1-for-46 reverse stock split which took effect on June 29,
2010).







INDEX


PagePART
      IItem
      1.
                                                                                                                Business.
                                                                                                                3Item
      1A.
                                                                                                                Risk
      Factors.
                                                                                                                6Item
      2.
                                                                                                                Properties.
                                                                                                                6Item
      3.
                                                                                                                Legal
      Proceedings.
                                                                                                                6PART
      IIItem
      5.
                                                                                                                Market
      for Registrant’s Common Equity, Related Stockholder Matters and Issuer
      Purchases of Equity Securities.
                                                                                                                6Item
      6.
                                                                                                                Selected
      Financial Data.
                                                                                                                7Item
      7.
                                                                                                                Management’s
      Discussion and Analysis of Financial Condition and Results of
      Operations.
                                                                                                                7Item
      7A.
                                                                                                                Quantitative
      and Qualitative Disclosures About Market Risk.
                                                                                                                12Item
      8.
                                                                                                                Financial
      Statements and Supplementary Data.
                                                                                                                12Item
      9.
                                                                                                                Changes
      in and Disagreements with Accountants on Accounting and Financial
      Disclosure.
                                                                                                                12Item
      9A(T)
                                                                                                                Controls
      and Procedures.
                                                                                                                12Item
      9B.
                                                                                                                Other
      Information.
                                                                                                                13PART
      IIIItem
      10.
                                                                                                                Directors,
      Executive Officers and Corporate Governance.
                                                                                                                13Item
      11.
                                                                                                                Executive
      Compensation.
                                                                                                                14Item
      12.
                                                                                                                Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters.
                                                                                                                16Item
      13.
                                                                                                                Certain
      Relationships and Related Transactions, and Director
      Independence.
                                                                                                                17Item
      14.
                                                                                                                Principal
      Accountant Fees and Services.
                                                                                                                18Item
      15.
                                                                                                                Exhibits
      and Financial Statement Schedules.
                                                                                                                19Signatures
                                                                                                                20


2


PART
I





Cautionary
Statements Regarding Forward Looking Statements





China
Domestica Bio-technology Holdings, Inc. (referred to herein as “we” or the
“Company”) desires to take advantage of the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. This report on Form 10-K may
contain forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are
intended to be covered by the safe harbors created thereby. Forward-looking
statements are not historical facts but instead represent only our belief
regarding future events, many of which, by their nature, are inherently
uncertain and outside of our control. These statements include statements other
than historical information or statements of current conditions and may relate
to our future plans, operations and objectives and results, among other things,
our plans to consider possible acquisitions, statements with respect to our
expectations or beliefs with respect to future competition and statements
concerning our need for and ability to attract additional capital.  We have
no duty to update these statements.  Actual future events, circumstances,
performance and trends could materially differ from those set forth in these
statements due to various factors, including the risks, uncertainties and other
factors discussed in Item 1A “Risk Factors” and Item 7 “Management’s Discussion
and Analysis of Financial Condition and Results of Operations.”





We
expressly qualify in their entirety all forward-looking statements attributable
to us or any person acting on our behalf by the cautionary statements contained
or referred to in this section.





Item
1.  Business.





Overview
and Recent History





China Domestica Bio-technology
Holdings, Inc. was incorporated in the State of Nevada on August 17, 2006 under
the name “Cienega Creek Holdings, Inc.”  The Company was previously
engaged in the computer software business.  On March 16, 2010, the
Company entered into a material definitive agreement (the “Belmont Stock
Purchase Agreement”) with Michael Klinicki and Belmont Partners, LLC (“Belmont”)
whereby Belmont purchased a controlling interest of the Company’s common stock
(the “Belmont Purchase Transaction”) from Michael Klinicki on March 18,
2010.  Pursuant to the Belmont Stock Purchase Agreement, Joseph Meuse,
a managing member of Belmont, was appointed as a member of the Company’s Board
of Directors and to the office of President and all other Directors and officers
of the Company resigned.  Concurrent with this change of management,
the Company moved its principal executive offices to 360 Main Street,
Washington, VA 22747.  Contemporaneously with the Belmont Purchase
Transaction, the Company changed its plan of business from the development and
marketing of computer software to seeking to acquire or merge with a
revenue-producing company.





On April
26, 2010, the Company entered into a Common Stock Purchase Agreement (the
“Purchase Agreement”) by and among China Sheng Yong Bio-Pharmaceutical Holding
Company Limited, or the “Buyer,” Belmont, or the Seller, and the
Company.  Pursuant to the terms of the Purchase Agreement, on April
26, 2010, the Buyer acquired from the Seller a controlling interest in the
Company’s common stock. Pursuant to the terms of the Purchase
Agreement, the Company agreed to issue to the Seller shares of its common
stock such that the Seller will own 5% of the issued and outstanding capital
stock of the Company after the closing of a merger transaction with an as of yet
unidentified target corporation contemplated by the Purchase
Agreement.  Pursuant to the terms of the Purchase Agreement, Joseph J.
Meuse resigned on the Closing Date and Qingyu Meng was named President and
Director of the Company and Yung Kong Chin was named Secretary and Director of
the Company.  Such resignation and appointments were effective as of
the Closing Date with respect to the officers of the Company.  The
resignation of Joseph J. Meuse as a director and the naming of Messrs. Meng and
Chin as directors took effect on May 22, 2010.  Concurrent with this
change of management, the Company moved its principal executive offices to Room
2303, 2304 ShenFang Square, 3005 RenMing Road South, LuFung District, Shenzhen,
China.  The Company’s telephone number is (86)
13168096855.  The Company’s fiscal year end is March
31.


3





On June 29, 2010, the Company amended
its articles of incorporation to change its name to “China Domestica
Bio-technology Holdings, Inc.,” to authorize the issuance of up to 10,000,000
shares of “blank check” preferred stock and to effect a 46-for-1 reverse stock
split of its outstanding shares of common stock.  A copy of the
amendment to the Company’s articles is included in Exhibit 3.1 to this Annual
Report.  The reverse stock split reduced the number of issued and
outstanding shares of our Common Stock from 2,294,250 shares outstanding prior
to the split to 49,896 shares outstanding after the split.  The
reverse stock split became effective on June 29, 2010.





From
inception to the present, the Company has not generated any revenue, and remains
a development stage business with limited operations.  We have limited
assets, and our prospects of future profitable operations may be delayed or
never realized. We may encounter difficulties that prevent us from operating our
business as intended or that will prevent us from doing so in a profitable
manner.  Our business must be evaluated in view of possible delays,
additional expenses, and other unforeseen complications that are often
encountered by new business ventures.





Selection
of a Business Combination





The
Company is currently seeking to acquire or merge with a revenue-producing
company.  Due to our lack of financial resources, the scope and number
of suitable business ventures is limited. We are therefore most likely to
participate in a single business venture.  Accordingly, the Company
will not initially be able to diversify and will be limited to one merger or
acquisition.  The lack of diversification will prevent us from offsetting
losses from one business opportunity against profits from another.





The
decision to participate in a specific business opportunity will be made upon
management’s analysis of the quality of the opportunity’s management and
personnel, the anticipated acceptability of products or marketing concepts, the
merit of technological changes and numerous other factors which are difficult,
if not impossible, to analyze through the application of any objective criteria.
 Further, it is anticipated that the historical operations of a specific
venture may not necessarily be indicative of the potential for the future
because of the necessity to substantially shift a marketing approach, expand
operations, change product emphasis, change or substantially augment management,
or make other changes.  The Company will be partially dependent upon the
management of any given business opportunity to identify such problems and to
implement, or be primarily responsible for the implementation of required
changes.





Since we
may participate in a business opportunity with a newly organized business or
with a business which is entering a new phase of growth, it should be emphasized
that the Company may incur risk due to the failure of the target’s management to
have proven its abilities or effectiveness, or the failure to establish a market
for the target’s products or services, or the failure to realize
profits.





The
Company will not acquire or merge with any company for which audited financial
statements cannot be obtained.  Management anticipates that any opportunity
in which we participate will present certain risks.  Many of these risks
cannot be adequately identified prior to selection of a specific opportunity.
 Our shareholders must therefore depend on the ability of management to
identify and evaluate such risks.  Further, in the case of some of the
opportunities available to us, it may be anticipated that some of such
opportunities are yet to develop as going concerns or that some of such
opportunities are in the development stage in that same have not generated
significant revenues from principal business activities prior to our
participation.


4





Acquisition
of Business





Implementation
of a structure for any particular business acquisition may involve a merger,
consolidation, reorganization, joint venture, franchise or licensing agreement
with another corporation or entity. The Company may also purchase stock or
assets of an existing business. On the completion of a transaction, it is
possible that present management and shareholders of the Company would not
remain in control of the Company. Further, our officers and directors may, as
part of the terms of any transaction, resign, to be replaced by new officers and
directors.





We
anticipate that any securities issued in any such reorganization would be issued
in reliance on exemptions from registration under applicable federal and state
securities laws. However, in certain circumstances, as a negotiated element of
any transaction, the Company may agree to register securities either at the time
a transaction is consummated, under certain conditions, or at a specified time
thereafter.  The issuance of substantial additional securities and their
potential sale into any trading market may have a depressive effect on such
market.





While the
actual terms of a transaction to which the Company may be a party cannot be
predicted, it may be expected that the parties to a business transaction will
find it desirable to avoid the creation of a taxable event and thereby structure
the acquisition in a so called “tax-free” reorganization under Section 368(a)(1)
of the Internal Revenue Code of 1986, as amended (the “Code”). In order to
obtain tax-free treatment under the Code, it may be necessary for the owners of
the acquired business to own 80% or more of the voting stock of the surviving
entity. In such event, our shareholders would retain less than 20% of the issued
and outstanding shares of the surviving entity, which could result in
significant dilution in the equity of such shareholders.





The
manner in which we participate in an opportunity will depend on the nature of
the opportunity and the respective needs and desires of the Company and other
parties. Negotiations that involve mergers or acquisitions will focus on the
percentage of the Company that the target company shareholders would acquire in
exchange for their shareholdings in the target company. Depending upon, among
other things, the target company’s assets and liabilities, our shareholders will
in all likelihood hold a lesser percentage ownership interest in the Company
following any merger or acquisition. The percentage ownership may be subject to
significant reduction in the event the Company acquires a target company with
substantial assets. Any merger or acquisition effected by the Company can be
expected to have a significant dilutive effect on the percentage of shares held
by our current shareholders.





Operation of Business after
Acquisition





The
Company’s operation following its merger or acquisition of a business will be
dependent on the nature of the business and the interest acquired. We are unable
to determine at this time whether the Company will be in control of the business
or whether present management will be in control of the Company following the
acquisition. We may expect that any future business will present various
challenges that cannot be predicted at the present time.




5




Competition





We will
be involved in intense competition with other business entities to obtain a
suitable business opportunity, many of which competitors will have a
considerable edge over us by virtue of their stronger financial resources and
prior experience in business.





Employees





At this
time we have no employees.  All of our activities are carried out by our
officers and directors.





How
to Obtain Our SEC Filings





We file
annual, quarterly, and special reports, proxy statements, and other information
with the Securities and Exchange Commission (SEC).  Reports, proxy
statements and other information filed with the SEC can be inspected and copied
at the public reference facilities of the SEC at 100 F Street N.E., Washington,
DC 20549. Such material may also be accessed electronically by means of the
SEC's website at www.sec.gov.





Item
1A. Risk Factors.





As a
smaller reporting company, we are not required to provide risk
factors.





Item
2.  Properties.





We
do not own any properties.  During fiscal year 2010 we leased office
space from our former President Michael Klinicki on a rent-free basis in Mr.
Klinicki’s residence without any lease agreement or obligation.  On
March 16, 2010, we moved our headquarters to office space owned by our then sole
officer and Director Joseph J. Meuse and continued to have no lease agreement or
obligation.  On April 26, 2010, we moved our headquarters to office
space occupied by Qingyu Meng, our President, and continue to have no lease
agreement or obligation.





Item
3.  Legal Proceedings.





We are
not currently involved in any material pending legal proceeding.





PART
II





Item
5.  Market for Registrant's Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.





Market
Information





The
Company's common shares are quoted on the inter-dealer electronic quotation
and trading system maintained by Pink OTC Markets Inc. under the ticker
symbol “CDBH.”  The following table shows, for the calendar periods
indicated, the range of reported high and low bid quotations for those shares.
Such prices reflect inter dealer prices, without retail markup, mark-down or
commission and may not necessarily represent actual transactions, and do reflect
the 46-for-1 reverse stock split of the Company’s common shares
which took effect on June 29, 2010.


6





For
      the Fiscal Year ended
                    March
      31, 2010
                  
                  
                  For
      the Fiscal Year ended
                    March
      31, 2009High
      Bid
                  
                  
                  Low
      Bid
                  
                  
                  High
      Bid
                  
                  
                  Low
      Bid1st
      Quarter
                  
                  
                  .51
                  
                  
                  
                  .17
                  
                  
                  
                  N/A
                  
                  
                  
                  N/A2nd
      Quarter
                  
                  
                  .43
                  
                  
                  
                  .145
                  
                  
                  
                  .95
                  
                  
                  
                  .103rd
      Quarter
                  
                  
                  .51
                  
                  
                  
                  .05
                  
                  
                  
                  .90
                  
                  
                  
                  .154th
      Quarter
                  
                  
                  .51
                  
                  
                  
                  .05
                  
                  
                  
                  .45
                  
                  
                  
                  .17





Holders





As of
August 5, 2010, there were approximately 26 record holders of the Company’s
Common Stock as reflected on the books of the Company's transfer
agent.





Dividends





The
Company had not paid any dividends on its Common Stock and the Board of
Directors of the Company presently intends not to declare dividends, but to
pursue a policy of retaining earnings, if any, for use in the Company's
operations and to finance expansion of its business.  The declaration
and payment of dividends in the future on the Common Stock will be determined by
the Board of Directors in light of conditions then existing, including the
Company's earnings, financial condition, capital requirements and other
factors.





Securities
Authorized for Issuance Under Equity Compensation Plans





As of
March 31, 2010, we had no equity compensation arrangements or plans either
approved or not approved by our stockholders.  We granted no options
during our fiscal year ended March 31, 2010 and had no options outstanding as of
March 31, 2010.





Item
6. Selected Financial Data.





Not
applicable.





Item
7. Management's Discussion and Analysis of Financial Condition and Results of
Operations.





The
following discussion and analysis should be read together with the factors
discussed in Item 1A “Risk Factors” and with the financial statements, including
the notes thereto, and the other financial information appearing elsewhere in
this Report. Period-to-period comparisons of financial data are not necessarily
indicative, and therefore should not be relied upon as indicators, of the
Company’s future performance. Words or phrases such as “believes,” “does not
believe,” “will,” “may,” “plan,” “estimate,” “anticipate,” “expect,” “intend”
and similar expressions may identify “forward-looking statements.”





7




Recent
Developments


China
Domestica Bio-technology Holdings, Inc. was incorporated in the State of Nevada
on August 17, 2006 under the name “Cienega Creek Holdings, Inc.”  The
Company was previously engaged in the computer software business.  On
March 16, 2010, the Company entered into a material definitive agreement (the
“Belmont Stock Purchase Agreement”) with Michael Klinicki and Belmont Partners,
LLC (“Belmont”) whereby Belmont purchased a controlling interest of the
Company’s common stock (the “Belmont Purchase Transaction”) from Michael
Klinicki on March 18, 2010.  Pursuant to the Belmont Stock Purchase
Agreement, Joseph Meuse, a managing member of Belmont, was appointed as a member
of the Company’s Board of Directors and to the office of President and all other
Directors and officers of the Company resigned.  Concurrent with this
change of management, the Company moved its principal executive offices to 360
Main Street, Washington, VA 22747.  Contemporaneously with the Belmont
Purchase Transaction, the Company changed its plan of business from the
development and marketing of computer software to seeking to acquire or merge
with a revenue-producing company.





On April
26, 2010, the Company entered into a Common Stock Purchase Agreement (the
“Purchase Agreement”) by and among China Sheng Yong Bio-Pharmaceutical Holding
Company Limited, or the “Buyer,” Belmont, or the Seller, and the
Company.  Pursuant to the terms of the Purchase Agreement, on April
26, 2010, the Buyer acquired from the Seller a controlling interest in the
Company’s common stock. Pursuant to the terms of the Purchase
Agreement, the Company agreed to issue to the Seller shares of its common
stock such that the Seller will own 5% of the issued and outstanding capital
stock of the Company after the closing of a merger transaction with an as of yet
unidentified target corporation contemplated by the Purchase
Agreement.  Pursuant to the terms of the Purchase Agreement, Joseph J.
Meuse resigned on the Closing Date and Qingyu Meng was named President and
Director of the Company and Yung Kong Chin was named Secretary and Director of
the Company.  Such resignation and appointments were effective as of
the Closing Date with respect to the officers of the Company.  The
resignation of Joseph J. Meuse as a director and the naming of Messrs. Meng and
Chin as directors took effect on May 22, 2010.  Concurrent with this
change of management, the Company moved its principal executive offices to Room
2303, 2304 ShenFang Square, 3005 RenMing Road South, LuFung District, Shenzhen,
China.  The Company’s telephone number is (86)
13168096855.  The Company’s fiscal year end is March 31.





On June
29, 2010, the Company amended its articles of incorporation to change its name
to “China Domestica Bio-technology Holdings, Inc.,” to authorize the issuance of
up to 10,000,000 shares of “blank check” preferred stock and to effect a
46-for-1 reverse stock split of its outstanding shares of common
stock.  A copy of the amendment to the Company’s articles is included
in Exhibit 3.1 to this Annual Report.  The reverse stock split reduced
the number of issued and outstanding shares of our Common Stock from 2,294,250
shares outstanding prior to the split to 49,896 shares outstanding after the
split.  The reverse stock split became effective on June 29,
2010.





Plan
of Operations





We are a
start-up, development-stage corporation and have not yet generated or realized
any revenues from our business operations.





Whereas
sales and marketing activities were our focus during fiscal 2009, we were unable
to realize any revenues during fiscal 2010 as a result of these activities. As a
result of our lack of revenues and inability to secure additional funding to
allow business operations to continue, our Board of Directors determined that it
was necessary to terminate the execution of our prior business plan, and that a
change in business focus was needed and in the best interests of the Company and
its shareholders. The goal of the new business plan is to merge with or acquire
a revenue-producing business or a development stage business with a high
potential for growth.





We will
need additional capital in fiscal 2011. As of March 31, 2010, we had $215 in
cash and cash equivalents. During the most recent fiscal year, we made certain
cost reductions. We have no remaining employees. Our former CEO Michael Klinicki
agreed to terminate his employment agreement effective as of January 1, 2010.


8





Although
we continue to look for ways to raise additional capital, we recognize that it
is not likely this will be successful.  As an alternative strategy, we
have decided to focus on identifying suitable candidates to merge with or
acquire.  We believe that our ability to continue to operate depends on
finding a suitable merger target with the ability to raise additional needed
capital.  Notwithstanding the elimination of most of our remaining
expenses, we may need additional cash during the next twelve months.  As a
result of our current limited cash availability we do not anticipate hiring any
employees for the foreseeable future.





Results
of Operations





Year
Ended March 31, 2010 Compared to the Year Ended March 31, 2009





For the year ended March 31, 2010, we
incurred a net loss of approximately $60,519, which was approximately $289,088
less, or 83% less than the prior year’s loss of $349,607.  During the
year ended  March 31, 2009, the Company’s activities were focused on
administrative activities and developing our sales and marketing
capabilities.  During the most recent year, we terminated our one
employee pursuant to the change in our business focus, and our expenses were
primarily a result of salary paid to our CEO before his employment agreement was
terminated and professional fees associated with being a public
company.





Operating
expenses for the year ended March 31, 2010 of $59,015 decreased $289,382 from
those of $348,397 for the year ended March 31, 2009 due primarily to: an
increase in salary expenses from $12,500 in 2009 versus $37,500 in 2010, a
decrease in professional fees from $17,162 in 2009 versus $13,424 in 2010, a
decrease in professional fees to a related party from $304,250 in 2009 to $0 in
2010, an increase in depreciation expense from $924 in 2009 to $1,664 in 2010,
and a decrease in general and administrative expenses from $13,561 in 2009 to
$6,427 in 2010.





Liquidity and Capital
Resources





At its
current level of operations, the Company will need to begin profitable
operations and/or raise additional capital during the next fiscal
year.  As of March 31, 2010, the Company had not generated any revenue
and had $215 in cash and cash equivalents and owed accounts payable and accrued
liabilities of $200 and owed $4,600 to Michael Klinicki pursuant to a note.
In
September 2010, Mr. Klinicki agreed to the cancellation of all debts owed to him
under this note.Despite the reductions in expenses mentioned above, we
will not have enough capital resources available to continue operating through
the end of our next fiscal year.  We estimate that we will require
minimum additional funding in fiscal year 2011 of approximately $30,000 to fund
our operations.  Our ability to continue operating depends on our
ability to locate and merge with a business generating revenues.  If
the Company is successful in finding a suitable merger target, it may result in
significant dilution to existing shareholders.





Going Concern





We
incurred a net loss of approximately $60,519 for the fiscal year ended March 31,
2010, and a cumulative net loss of approximately $433,510 since inception
(August 17, 2006) through March 31, 2010, and there is substantial doubt about
our ability to continue as a going concern.  As of March 31, 2010, we
had approximately $215 in cash and cash equivalents.  In order to
continue to operate we need to develop additional sources of capital and to
ultimately achieve profitable operations. We do not have sufficient resources to
fund our operations for the next twelve months.





We
estimate that we will require minimum funding in fiscal year 2011 of
approximately $30,000 in order to fund our operations.  Although we
are actively seeking new sources of equity and reduce our expenses while seeking
a suitable merger candidate,  there can be no assurances that we will
be able to raise additional capital on terms that are acceptable to us or at
all.  Additionally, there can be no assurance that we will be able to
find a suitable merger candidate.


9





Current
market conditions, continued negative cash flows and lack of liquidity create
significant uncertainty about the our ability to fully implement our operating
plan, as a result of which we may have to further reduce the scope of our
operations.





Critical
Accounting Policies





Restatement
of Financial Statements





On
September 29, 2009, the Company discovered a material error in its accounting
that resulted in a misstatement of the financial statements for the fiscal year
ended March 31, 2009. The Company failed to record a prepaid expense for officer
salaries resulting in an understatement of current assets and an overstatement
of operating expenses of $37,500. The Company revalued shares issued for
services increasing professional fees and Additional Paid-in Capital by
$249,000. The Company also has corrected several smaller errors including
certain unrecorded liabilities, property and equipment, and accounts payable. In
the year ended March 31, 2009 these errors resulted in the understatement of
property and equipment by $960, an understatement of total liabilities by $1,973
and understatement of net loss by $1,013. The financial statements for the
fiscal year ended March 31, 2009, have been restated to reflect these
errors.





Cash
and Cash Equivalents





For
Statement of Cash Flows purposes, the Company considers all cash on hand and in
banks, certificates of deposit and other highly-liquid investments with
maturities of three months or less, when purchased, to be cash and cash
equivalents.





Property
and Equipment





Property
and equipment are stated at cost. Depreciation has been calculated over the
estimated useful lives of the assets ranging of 5 years using the straight line
method.  The cost of maintenance and repairs is expensed as
incurred.





Impairment
of Long-Lived Assets





The
Company continually monitors events and changes in circumstances that could
indicate carrying amounts of long-lived assets may not be recoverable. When such
events or changes in circumstances are present, the Company assesses the
recoverability of long-lived assets by determining whether the carrying value of
such assets will be recovered through undiscounted expected future cash flows.
If the total of the future cash flows is less than the carrying amount of those
assets, the Company recognizes an impairment loss based on the excess of the
carrying amount over the fair value of the assets. Assets to be disposed of are
reported at the lower of the carrying amount or the fair value less costs to
sell.





Advertising
Costs





The
Company's policy regarding advertising is to expense advertising when incurred.
The Company has incurred no advertising expenses during the year ended March 31,
2010 and $1,856 during the year ended March 31, 2009.


10






Revenue
Recognition
  Presently,
the Company is in the development stage and as such, has no
revenues.  Upon emerging from the development stage the Company will
adopt a policy of recognizing revenue when a definitive agreement with a
determinable price exists, product delivery and/or invoicing (in each case where
there is reasonable assurance of meeting customer-specified criteria) has
occurred, and the collectibility of the invoice is reasonably
assured.




Income
Taxes





The
Company uses the asset and liability method of accounting for income taxes. At
March 31, 2010, respectively, the deferred tax asset and deferred tax liability
accounts, as recorded when material to the financial statements, are entirely
the result of temporary differences.  Temporary differences represent
differences in the recognition of assets and liabilities for tax and financial
reporting purposes, primarily accumulated depreciation and
amortization.





As of
March 31, 2010, the deferred tax asset related to the Company's net operating
loss carryforward is fully reserved.  Due to the provisions of
Internal Revenue Code Section 338, the Company may have no net operating loss
carryforwards available to offset financial statement or tax return taxable
income in future periods as a result of a change in control involving 50
percentage points or more of the issued and outstanding securities of the
Company.





Dividends





The
Company is a Development Stage Company and has not yet adopted a policy
regarding the payment of dividends.




Foreign
Currency Translation





The
financial statements are presented in United States dollars. During the
fiscal year ended, March 31, 2010, the Company was a United States Company and
accounted for in US Dollars. Effective with the acquisition of the Company on
April 26, 2010, in conjunction with the Common Stock Purchase Agreement, the
Company will be changing its’ functional currency to
the Chinese Renminbi (RMB) as the Company will be domiciled in the People’s
Republic of China (PRC).  This change in functional currency results in a
change in accounting principle and pursuant to current accounting literature
(ASC 250) changes should be accounted for retrospectively to all prior periods,
unless it is impractical to do so.  It was determined impracticable to
determine the cumulative effect if this change in accounting principle and the
retroactive application of this change to prior years, because the Company’s
accounting records do not provide sufficient information to apply this change in
functional currency.  As a result, this change will be applied
prospectively to the fiscal year ended, March 31, 2011.




In
accordance with FASB ASC 830, “Foreign Currency Translation”, foreign
denominated monetary assets and liabilities are translated into their United
States dollar equivalents using foreign exchange rates which prevailed at the
balance sheet date.  Non monetary assets are translated at the
exchange rates prevailing at the transaction date.  Revenue and
expenses are translated at average rates of exchange during the
year.  Gains or losses resulting from foreign currency transactions
are included in results of operations.





Earnings
(Loss) per Share





Basic
earnings (loss) per share is computed by dividing the net income (loss)
available to common shareholders by the weighted-average number of common shares
outstanding during the respective period presented in our accompanying financial
statements.





Fully
diluted earnings (loss) per share is computed similar to basic income (loss) per
share except that the denominator is increased to include the number of common
stock equivalents (primarily outstanding options and warrants).





Common
stock equivalents represent the dilutive effect of the assumed exercise of
outstanding stock options and warrants, using the treasury stock method, at
either the beginning of the respective period presented or the date of issuance,
whichever is later, and only if the common stock equivalents are considered
dilutive based upon the Company’s net income (loss) position at the calculation
date.





As of
March 31, 2010, the Company has no issued and outstanding warrants or
options.




Use
of Estimates





The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.





Recent
Accounting Pronouncements





The
Company’s management has evaluated recently issued accounting standards through
the filing date of these financial statements and believes that the recently
issued accounting standards will not have a material impact on the Company’s
financial position, operations, or cash flows.





Inflation





We
believe that inflation has not had a material effect on our operations to
date.





11


Item
7A. Quantitative and Qualitative Disclosures about Market Risk.





Not
applicable.





Item
8. Financial Statements and Supplementary Data.





The
Financial Statements are filed as part of this Annual Report on Form
10-K.





Item
9.  Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.





Not
applicable.




Item
9A(T). Controls and Procedures.





Evaluation
of Disclosure Controls and Procedures


Under the
supervision and with the participation of our management, including our
principal executive officer and the principal financial officer (our President
and Secretary, respectively), we have conducted an evaluation of the
effectiveness of the design and operation of our disclosure controls and
procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act,
as of the end of the period covered by this report. Based on this evaluation,
our principal executive officer and principal financial officer concluded as of
the evaluation date that our disclosure controls and procedures were effective
such that the material information required to be included in our Securities and
Exchange Commission reports is accumulated and communicated to our management,
including our principal executive and financial officer, recorded, processed,
summarized and reported within the time periods specified in Securities and
Exchange Commission rules and forms relating to our company, particularly during
the period when this report was being prepared.





Management’s
Annual Report on Internal Control Over Financial Reporting





Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting, as such term is defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act, for the company.





Internal
control over financial reporting includes those policies and procedures that:
(1) pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of our assets; (2) provide
reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted
accounting principles, and that our receipts and expenditures are being made
only in accordance with authorizations of its management and directors; and (3)
provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of our assets that could have a
material effect on the financial statements.





Management
recognizes that there are inherent limitations in the effectiveness of any
system of internal control, and accordingly, even effective internal control can
provide only reasonable assurance with respect to financial statement
preparation and may not prevent or detect material misstatements. In addition,
effective internal control at a point in time may become ineffective in future
periods because of changes in conditions or due to deterioration in the degree
of compliance with our established policies and procedures.





A
material weakness is a significant deficiency, or combination of significant
deficiencies, that results in there being a more than remote likelihood that a
material misstatement of the annual or interim financial statements will not be
prevented or detected.





Under the
supervision and with the participation of our president, management conducted an
evaluation of the effectiveness of our internal control over financial
reporting, as of March 31, 2010, based on the framework set forth in Internal
Control-Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO). Based on our evaluation under this framework,
management concluded that our internal control over financial reporting was not
effective as of the evaluation date due to the factors stated
below.





Management
assessed the effectiveness of the Company's internal control over financial
reporting as of evaluation date and identified the following material
weaknesses:





Insufficient Resources: We
have an inadequate number of personnel with requisite expertise in the key
functional areas of finance and accounting.





Inadequate Segregation of
Duties: We have an inadequate number of personnel to properly implement
control procedures.


12





Lack of Audit Committee and Outside
Directors on the Company’s Board of Directors:  We do not have
a functioning audit committee or outside directors on our board of directors,
resulting in ineffective oversight in the establishment and monitoring of
required internal controls and procedures.





Insufficient Written
Policies: We have insufficient written policies and procedures for
accounting and financial reporting with respect to the requirements and
application of US GAAP and SEC disclosure requirements.





Management
is committed to improving its internal controls and will (1) continue to use
third party specialists to address shortfalls in staffing and to assist the
Company with accounting and finance responsibilities, (2) increase the frequency
of independent reconciliations of significant accounts which will mitigate the
lack of segregation of duties until there are sufficient personnel and (3) may
consider appointing outside directors and audit committee members in the
future.





Management,
including our president, has discussed the material weaknesses noted above with
our independent registered public accounting firm. Due to the nature of this
material weakness, there is a more than remote likelihood that misstatements
which could be material to the annual or interim financial statements could
occur that would not be prevented or detected.





This
annual report does not include an attestation report of our registered public
accounting firm regarding internal control over financial
reporting.  Management’s report was not subject to attestation by the
our registered public accounting firm pursuant to temporary rules of the SEC
that permit us to provide only management's report in this annual
report.





Changes
in Internal Controls Over Financial Reporting





There
have been no changes in our internal control over financial reporting that
occurred during the last fiscal quarter for our fiscal year ended March 31, 2010
that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.





Item
9B. Other Information.





Not
applicable.





PART
III





Item
10.  Directors, Executive Officers, and Corporate
Governance.





Directors
and Executive Officers





The
following table sets forth, as of September 7, 2010, the name, age and position
for each executive officer and Director of the Company.  Our executive
officers and Directors serve until death, removal or resignation or until their
successors have been duly elected and have qualified.





NAME
            
            AGE
            
            POSITIONQingyu
      Meng
            
            41
            
            Director
      and PresidentYung
      Kong Chin
            
            57
            
            Director
      and Secretary





Information
regarding the business backgrounds of our directors and executive officers is
set forth below.


13





Qingyu MengMr. Meng has served as our President since April 2010 and a Director of
the Company since June 2010.  Mr. Meng is a Master’s Degree candidate
with a bio-pharmaceuticals major in the life science college, Heilongjiang
August First Land Reclamation University.  Since 2001, he has
specialized in housefly bio-active proteins’ medical application research in the
area of molecular biology. He is the member of Heilongjiang Provincial Hospital
Management Association Professional Committee of Clinical Nutrition; the
managing director of Daqing Nutrition Society; a technology partner of State Key
Protein Structure Laboratory; and he independently has four national invention
patents of full housefly bio-active proteins.  Since 2005, he has been
the chairman and president of China Housefly Biotechnology Holding
Company.





Yung Kong
Chin    Mr. Chin has served as our Secretary since
April 2010 and a Director of the Company since June 2010.  Mr. Chin
graduated from the University of Hull in the United Kingdom with a Master of
Finance.  Mr. Chin served as president of QMIS Capital Finance Pty.
Ltd. in Singapore and QMIS Capital Finance Investment Inc. from 2003 to the
present.  Before joining QMIS, he was a financial controller for the
Kwok Group company in China.





Family
Relationships





There is
no family relationship among any of our officers or directors.





Involvement
in Certain Legal Proceedings





No director or executive officer has
been convicted of a criminal offense within the past ten years or is the subject
of a pending criminal proceeding. No director or executive officer has been the
subject of any order, judgment or decree of any court permanently or temporarily
enjoining, barring, suspending or otherwise limiting his involvement in any type
of business, securities or banking activities. No director or officer has been
found by a court to have violated a federal or state securities or commodities
law.





Section
16(a) Beneficial Ownership Reporting Compliance





Section
16(a) of the Exchange Act requires the Company’s directors and officers and
holders of more than 10% of the issued and outstanding shares of our Common
Stock to file with the SEC initial reports of ownership, and reports of changes
in ownership, of common stock and other equity securities of the Company. Based
solely on our review of copies of the reports by some of those persons, the
Company believes that, during fiscal year 2010, all of its directors and
officers and holders of more than 10% of the issued and outstanding shares of
our common stock complied with all reporting requirements under Section 16(a),
except that Michael Klinicki did not file a Section 16 report in connection with
the disposition of his shares of Common Stock in the Company on March 18,
2010.





Code
of Ethics





We do not
currently have a code of ethics.  Because we have only limited
business operations and only two officers and directors, we believe a code of
ethics would have limited utility at this time.





Item
11. Executive Compensation.





The
following table shows the compensation of our executive officers for the fiscal
years ended March 31, 2010 and March 31, 2009:


14





Summary
      Compensation TableName and Principal Position
                              
                              Year
                              
                              Salary ($)
                              
                              
                              Stock
                                Awards
                              
                              
                              All Other
                                CompensationMichael
      Klinicki,Former
      President, Chief Executive
                              
                              2010
                              
                              $
                              37,500
                              
                              
                              
                              -0-
                              
                              
                              
                              -0-Officer,
      Chief Financial Officer,
                              
                              2009
                              
                              $
                              12,500
                              
                              
                              $
                              250,000
                              
                              
                              $
                              54,250Secretary,
      Treasurer, DirectorJoseph
      J. MeuseDirector,
      former President
                              
                              2010
                              
                              
                              -0-
                              
                              
                              
                              -0-
                              
                              
                              
                              -0-




On January 1, 2009, the Company issued
to Michael Klinicki, its former CEO, 1,000,000 shares of its common stock in
consideration for his services as an officer and for meeting certain
milestones.  The shares of common stock were valued at $250,000 in
accordance with FASB ASC 718.





Michael
Klinicki received additional compensation from the Company indirectly by means
of payments from the Company to his wholly-owned company Riparian Technologies,
in consideration for services supplied by Riparian Technologies to the Company
with respect to website development and maintenance, financial statement
preparation, SEC reporting and preparation of press releases.  The
Company made payments to Riparian Technologies totaling $0 in the year ended
March 31, 2010 and $54,250 in the year ended March 31, 2009, which amounts are
included in “All Other Compensation” above.





Employment
Agreements





At
present, the Company is operated by its executive officers and directors without
compensation and the Company is currently not a party to any employment
agreements.  On December 4, 2008, the Company entered into an
Employment Agreement, effective January 1, 2009, with its former CEO, Michael
Klinicki, which provided for an annual salary of $50,000 and severance payments
equal to twelve months of salary in the event Mr. Klinicki was terminated by the
Company for any reason, including a change of control.  This
Employment Agreement was terminated effective January 1, 2010, pursuant to a
Termination of Employment letter dated December 2, 2009 between the Company and
Mr. Klinicki.  Pursuant to the terms of the Termination of Employment
letter, Mr. Klinicki waived his rights to severance payments he had under the
Employment Agreement.





Equity
Compensation Plans





As of
March 31, 2010, we had no equity compensation arrangements or plans and no
options outstanding to purchase shares of our Common Stock.  During
the fiscal years ended March 31, 2010, and March 31, 2009, we have not granted
any stock options to our named executive officers.  During our fiscal
year ended March 31, 2010, none of our named executive officers or directors
exercised any options to purchase shares of our Common
Stock.





Director
Compensation





Directors
of our Company are not compensated in cash for their services but are reimbursed
for out-of-pocket expenses incurred in furtherance of our
business.


15





Item
12. Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters.





The
following table sets forth information regarding beneficial ownership of our
common stock as of August 5, 2010 (i) by each person who is known by us to
beneficially own more than 5% of our common stock; (ii) by each of our officers
and directors; and (iii) by all of our officers and directors as a
group.  Unless otherwise specified, the address of each of the persons
set forth below is in care of the Company, Room 2303, 2304 ShenFang Square, 3005
RenMing Road South, LuFung District, Shenzhen, China 518001. Except as indicated
in the footnotes to this table and subject to applicable community property
laws, the persons named in the table to our knowledge have sole voting and
investment power with respect to all shares of securities shown as beneficially
owned by them. The information in this table is as of August 5, 2010 based upon
49,896 shares of common stock outstanding.





Name and Address of Beneficial Owner
                                              
                                              Office, If Any
                                              
                                              Amount and
                                                Nature of
                                                Beneficial
                                                Ownership
                                              
                                              
                                              Percent
                                                Common StockOfficers
      and DirectorsQingyu
      Meng
                                              
                                              President
      and Director
                                              
                                              
                                              28,240
                                              (1)
                                              
                                              
                                              56.6
                                              %(1)Yung
      Kong Chin
                                              
                                              Secretary
      and Director
                                              
                                              
                                              28,240
                                              (2)
                                              
                                              
                                              56.6
                                              %(2)Joseph
      Meuse
                                                360
      Main Street
                                                PO
      Box 393
                                                Washington,
      Virginia 22747
                                              
                                              Former
      President
                                              
                                              
                                              -
                                              (3)
                                              
                                              
                                              -
                                              (3)Michael
      A. Klinicki
                                                9181
      S. Antler Crest Drive
                                                Vail,
      Arizona 85641
                                              
                                              Former
      CEO
                                              
                                              
                                              2,174
                                              
                                              
                                              
                                              4.4
                                              %All
      officers and directors as a group (four persons named
    above)
                                              
                                              
                                              
                                              
                                              30,414
                                              
                                              
                                              
                                              61.0
                                              %5%
      Security HoldersChina
      Sheng Yong Bio-pharmaceutical Holding Company Limited
                                              
                                              
                                              
                                              
                                              28,240
                                              
                                              
                                              
                                              56.6
                                              %





* Less
than 1%


-
N/A





(1)  Mr.
Meng is a director and President of China Sheng Yong Bio-pharmaceutical Holding
Company Limited, which is the owner of 28,240 shares of the Company’s common
stock.





(2)  Mr.
Chin is a director and Secretary of China Sheng Yong Bio-pharmaceutical
Holding Company Limited, which is the owner of 28,240 shares of the Company’s
common stock.


16





(3)  Mr.
Meuse is a Managing Member of Belmont Partners, LLC, to which the Company is
obligated to issue shares of its common stock such that the Belmont Partners,
LLC will own 5% of the issued and outstanding capital stock of the Company after
the closing of a merger transaction with an as of yet unidentified target
corporation contemplated by the Purchase Agreement.  As there is no
right to acquire such shares within 60 days and the actual number of shares to
be issued cannot be determined until the time of such merger, such shares have
not been included in the numbers of shares listed in the table.




Item
13. Certain Relationships and Related Transactions, and Director
Independence.





Transactions
with Related Persons





The
following includes a summary of transactions since the beginning of the fiscal
year ending March 31, 2009, or any currently proposed transaction, in which we
were or are to be a participant and the amount involved exceeded or exceeds the
lesser of $120,000 or one percent of the average of our total assets at year end
for the last two completed fiscal years, and in which any related person had or
will have a direct or indirect material interest (other than compensation
described under “Executive Compensation”). We believe the terms obtained or
consideration that we paid or received, as applicable, in connection with the
transactions described below were comparable to terms available or the amounts
that would be paid or received, as applicable, in arm’s-length
transactions.





On April
26, 2010, the Company entered into the Purchase Agreement by and
among China Sheng Yong Bio-pharmaceutical Holding Company Limited, or the
Buyer, Belmont Partners, LLC, or the Seller, and the
Company.  Pursuant to the terms of the Purchase Agreement, on April
26, 2010, the Buyer acquired from the Seller 1,299,000 shares, or approximately
56.62%, of the issued and outstanding common stock of the Company.  In
consideration for the sale of the Purchased Stock, the Buyer paid the Seller
$280,000 and the Company agreed to issue to the Seller shares of its common
stock such that the Seller will own 5% of the issued and outstanding capital
stock of the Company after the closing of a merger transaction with an as of yet
unidentified target corporation contemplated by the Purchase
Agreement.  Joseph J. Meuse, the former President and a current
director of the Company, is a managing member of the Seller.  The
closing of the sale of the Purchased Stock, and the appointment of Qingyu Meng
as President and Director of the Company and Yung Kong Chinas Secretary and
Director of the Company, resulted in a change in control of the
Company.  Qingyu Meng is a director and President of the Buyer
and Yung Kong Chin is a director and Secretary of the Buyer.





Our
former CEO and director Michael Klinicki loaned the Company a total of $9,100 as
of February 25, 2010.  These loans were evidenced by a note which is
noninterest-bearing, unsecured and due on demand.  Mr. Klinicki agreed
to waive repayment of $4,500 of such loans in March
2010.  Mr. Klinicki agreed to waive repayment of the remainder of such
loans in September 2010.As of September 7, 2010 and March 31, 2010, the
Company owed $0 and $4,600 to Mr. Klinicki, respectively.





During
the fiscal years ended March 31, 2010 and 2009, Michael Klinicki, our former CEO
and director, received additional compensation from the Company indirectly by
means of payments from the Company to his wholly-owned company Riparian
Technologies, in consideration for services supplied by Riparian Technologies to
the Company with respect to website development and maintenance, financial
statement preparation, SEC reporting and preparation of press
releases.  The Company made payments to Riparian Technologies totaling
$0 in the year ended March 31, 2010, $54,250 in the year ended March 31, 2009,
and $0 in the period subsequent to March 31, 2010 through the date of this
Report.  The Company has no further indebtedness to Riparian
Technologies at this time.





17




Insider
Transactions Policies and Procedures




The
Company does not currently have an insider transaction policy.





Director
Independence




We
currently do not have any independent directors, as the term “independent” is
defined by the rules of the American Stock Exchange.





Item
14. Principal Accountant Fees and Services





AUDIT AND
NON-AUDIT FEES





Aggregate
fees for professional services rendered for the Company by Moore &
Associates Chartered, the Company’s principal accountants until August 7, 2009,
and Seale and Beers, CPAs, the Company’s principal accountants from and after
August 7, 2009, for the years ended March 31, 2010 and 2009 are set forth
below.  During the year ended March 31, 2010, the Company paid $3,000
to Moore & Associates Chartered and $5,270 to Seale and Beers,
CPAs.





Year
      2010
                    
                    
                    Year
      2009AUDIT
      FEES
                    
                    $
                    8,270
                    
                    
                    $
                    7,000AUDIT-RELATED
      FEES
                    
                    $
                    0
                    
                    
                    $
                    0TAX
      FEES
                    
                    $
                    0
                    
                    
                    $
                    0ALL
      OTHER FEES
                    
                    $
                    0
                    
                    
                    $
                    0TOTAL
                    
                    $
                    8,270
                    
                    
                    $
                    7,000





Audit
Fees for the fiscal years ended March 31, 2010 and 2009 were for the audits of
the consolidated financial statements of the Company, quarterly review of the
financial statements included in Quarterly Reports on form 10-Q, consents, and
other assistance required to complete the year end audit of the consolidated
financial statements.  Amounts included are for the respective year's
audit work.





Audit-Related
Fees as of the years ended March 31, 2010 and 2009 would have been for assurance
and related services reasonably related to the performance of the audit or
reviews of financial statements and not reported under the caption Audit
Fees.





Tax Fees
as of the years ended March 31, 2010 and 2009 were for professional services
related to tax compliance, tax authority audit support and tax
planning.  Amounts are included in the year billed.





As the
company does not have a formal audit committee, the services described above
were not approved by the audit committee under the de minimus exception provided
by Rule 2-01 (c) (7) (i) (C) under Regulation S-X.


18




PART
IV





Item
15. Exhibits and Financial Statement Schedules





I.  Listing
of Documents




(1)
            Financial
      Statements.





Reports
of Independent Registered Public Accounting Firms





Balance
Sheets as of March 31, 2010 and 2009





Statements
of Operations for the Years Ended March 31, 2010 and 2009 and from Inception
(August 17, 2006) to March 31, 2010





Statement
of Stockholders’ Equity (Deficit) for the Years Ended March 31, 2010 and 2009
and from Inception (August 17, 2006) to March 31, 2010





Statements
of Cash Flows for the Years Ended March 31, 2010 and 2009 and from Inception
(August 17, 2006) to March 31, 2010





Notes to
Financial Statements




(3)
            The
      following Exhibits are filed as part of this report on Form
      10-K:





3.1*
                  Articles
      of Incorporation (as amended)3.2
                  By-Laws
      (incorporated by reference to Exhibit 3.2 to the Form SB-2 of the Company
      filed with the SEC on July 12, 2007)10.1
                  Employment
      Agreement dated December 4, 2008 between the Company and Michael Klinicki
      (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Company
      filed with the SEC on February 12, 2009)10.2*
                  Termination
      of Employment Letter dated December 2, 2009, between the Company and
      Michael Klinicki and related Letter dated January 1,
  201010.3
                  Common
      Stock Purchase Agreement dated April 26, 2010, by and among China Sheng
      Yong Bio-pharmaceutical Holding Company Limited, Belmont Partners, LLC and
      Cienega Creek Holdings, Inc. (incorporated by reference to Exhibit 10.1 to
      the Form 8-K of the Company filed with the SEC on April 28,
      2010)21
                  List
      of Subsidiaries (incorporated by reference to Exhibit 21 to the Form 10-K
      of the Company filed with the SEC on May 15, 2008)31.1*
                  Rule
      13a-14(a) Certification of Principal Executive Officer31.2*
                  Rule
      13a-14(a) Certification of Principal Financial Officer32.1*
                  Section
      1350 Certification of Principal Executive Officer32.2*
                  Section
      1350 Certification of Principal Financial
  Officer







*Filed
herewith.


19


SIGNATURES





Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.





CHINA
      DOMESTICA BIO-
                      TECHNOLOGY
      HOLDINGS, INC.Date:
      December 3, 2010
                    By:  /s/
      Qingyu MengQingyu
      Meng, President and
Director





Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.





Date:
      December 3, 2010
                  By:  /s/
      Qingyu MengQingyu
      Meng, President and
Director





Date:
      December 3, 2010
                  By:  /s/
      Yung Kong ChinYung
      Kong Chin, Secretary and
Director




20


CHINA
DOMESTICA BIO-TECHNOLOGY HOLDINGS, INC.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)





INDEX
TO FINANCIAL STATEMENTS





For
the Years Ended


March
31, 2010 and 2009




PageReport
      of Independent Registered Public Accounting Firm
                
                2Financial
      Statements:Balance
      Sheets as of March 31, 2010 and 2009
                
                3Statements
      of Operations for the years ended March 31, 2010 and
      2009and
      from Inception (August 17, 2006) to March 31, 2010
                
                4Statement
      of Stockholders’ Equity (Deficit) for the years ended March 31, 2010 and
      2009and
      from Inception (August 17, 2006) to March 31, 2010
                
                5Statements
      of Cash Flows for the years ended March 31, 2010 and
      2009and
      from Inception (August 17, 2006) to March 31, 2010
                
                6Notes
      to Financial Statements
                
                7


1




SEALE
AND BEERS, CPAs




PCAOB & CPAB REGISTERED
AUDITORS


www.sealebeers.com





REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM





To
the Board of Directors


China
Domestica Bio-technology Holdings, Inc.


(A
Development Stage Company)





We have
audited the accompanying balance sheets of China Domestica Bio-technology
Holdings, Inc. (A Development Stage Company) as of March 31, 2010 and 2009
(restated), and the related statements of operations, stockholders’ equity
(deficit) and cash flows for the years then ended March 31, 2010 and 2009
(restated) and for the period from inception on August 17, 2006 through March
31, 2010. These financial statements are the responsibility of the Company’s
management.  Our responsibility is to express an opinion on these
financial statements based on our audits.





We
conducted our audits in accordance with standards of the Public Company
Accounting Oversight Board (United States).  Those standards require
that we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement.  An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements.  An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation.  We believe that our audits provide a reasonable basis
for our opinion.





In our
opinion, the financial statements referred to above present fairly, in all
material respects, the financial position of China Domestica Bio-technology
Holdings, Inc. (A Development Stage Company) as of March 31, 2010 and 2009
(restated), and the related statements of operations, stockholders’ equity
(deficit) and cash flows for the years then ended March 31, 2010 and 2009
(restated) and for the period from inception on August 17, 2006 through March
31, 2010, in conformity with accounting principles generally accepted in the
United States of America.





As
discussed in Note 3 to the accompanying financial statements, the Company has
restated its 2009 financial statements, which were previously audited by other
independent auditors who have ceased operations.





The
accompanying financial statements have been prepared assuming that the Company
will continue as a going concern.  As discussed in Note 4 to the
financial statements, the Company has incurred significant losses since
inception and has not yet established a source of revenues sufficient to cover
operating expenses. These factors raise substantial doubt about its ability to
continue as a going concern.  Management’s plans concerning these
matters are also described in Note 4.  The financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.





/s/
Seale and Beers, CPAs





Seale and
Beers, CPAs


Las
Vegas, Nevada


August
31, 2010





50 S. Jones Blvd. Suite 202
Las Vegas, NV 89107 Phone: (888)727-8251 Fax: (888)782-2351




2




China
Domestica Bio-technology  Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Balance
Sheets


March
31, 2010 and 2009





March
      31,2010
                      
                      
                      2009(Restated)AssetsCurrent
      assetsCash
      and cash equivalents
                      
                      $
                      215
                      
                      
                      $
                      11,327Prepaid
      officer salary
                      
                      
                      -
                      
                      
                      
                      37,500Total
      current assets
                      
                      
                      215
                      
                      
                      
                      48,827Fixed
      assetsComputer
      equipment
                      
                      
                      -
                      
                      
                      
                      5,636Less:
      accumulated depreciation
                      
                      
                      -
                      
                      
                      
                      (1,056
                      )Net
      fixed assets
                      
                      
                      -
                      
                      
                      
                      4,580Total
      assets
                      
                      $
                      215
                      
                      
                      $
                      53,407Liabilities
      and Stockholders' DeficitLiabilitiesAccounts
      payable and accrued liabilities
                      
                      $
                      200
                      
                      
                      $
                      1,973Due
      to related parties
                      
                      
                      4,600
                      
                      
                      
                      -Total
      liabilities
                      
                      
                      4,800
                      
                      
                      
                      1,973Stockholders'
      equity (deficit)Common
      stock; par value $0.001; 75,000,000 shares authorized;
      49,896   shares issued and outstanding at March 31, 2010
      & 2009 (after effect of 1 for 46 Share reverse stock split occurring
      June 29, 2010), respectively
                      
                      
                      51
                      
                      
                      
                      51Additional
      paid-in capital
                      
                      
                      428,874
                      
                      
                      
                      424,374Accumulated
      deficit during the development stage
                      
                      
                      (433,510
                      )
                      
                      
                      (372,991
                      )Total
      stockholders' equity (deficit)
                      
                      
                      (4,585
                      )
                      
                      
                      51,434Total
      liabilities and stockholders' equity (deficit)
                      
                      $
                      215
                      
                      
                      $
                      53,407





The
accompanying notes are an integral part of these financial
statements.


3





China
Domestica Bio-technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Statements
of Operations


For
the Years Ended March 31, 2010 and 2009


and
from Inception (August 17, 2006) to March 31, 2010





For the
                                
                                
                                From InceptionYear Ended March 31,
                                
                                
                                (August 17, 2006) to2010
                                
                                
                                2009
                                
                                
                                March 31, 2010(Restated)Revenues
                                
                                $
                                -
                                
                                
                                $
                                -
                                
                                
                                $
                                -Operating
      expensesOfficer
      salaries
                                
                                
                                37,500
                                
                                
                                
                                12,500
                                
                                
                                
                                50,000Professional
      fees
                                
                                
                                13,424
                                
                                
                                
                                17,162
                                
                                
                                
                                36,855Professional
      fees related party
                                
                                
                                -
                                
                                
                                
                                304,250
                                
                                
                                
                                306,700Depreciation
      expense
                                
                                
                                1,664
                                
                                
                                
                                924
                                
                                
                                
                                2,936General
      & administrative expenses
                                
                                
                                6,427
                                
                                
                                
                                13,561
                                
                                
                                
                                35,716Total
      operating expenses
                                
                                
                                59,015
                                
                                
                                
                                348,397
                                
                                
                                
                                432,207Loss
      from operations
                                
                                
                                (59,015
                                )
                                
                                $
                                (348,397
                                )
                                
                                $
                                (432,207
                                )Other
      income (expense)Interest
      income
                                
                                
                                12
                                
                                
                                
                                117
                                
                                
                                
                                1,540Loss
      on disposal of fixed assets
                                
                                
                                (1,516
                                )
                                
                                
                                -
                                
                                
                                
                                (1,516
                                )Impairment
      expense
                                
                                
                                -
                                
                                
                                
                                (1,327
                                )
                                
                                
                                (1,327
                                )Total
      other income (expense)
                                
                                
                                (1,504
                                )
                                
                                
                                (1,210
                                )
                                
                                
                                (1,303
                                )Loss
      before income taxes
                                
                                
                                (60,519
                                )
                                
                                
                                (349,607
                                )
                                
                                
                                (433,510
                                )Provision
      (benefit) for income taxes
                                
                                
                                -
                                
                                
                                
                                -
                                
                                
                                
                                -Net
      loss
                                
                                $
                                (60,519
                                )
                                
                                $
                                (349,607
                                )
                                
                                $
                                (433,510
                                )Basic
      and fully diluted loss per common share:Earnings
      (loss) per common share
                                
                                $
                                (1.21
                                )
                                
                                $
                                (2.04
                                )Basic
      and fully diluted weighted averagecommon
      shares outstanding (after effect of 1 for 46 share reverse stock split
      occurring June 29, 2010)
                                
                                
                                49,896
                                
                                
                                
                                171,124





The
accompanying notes are an integral part of these financial
statements.


4





China
Domestica Bio-technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Statement
of Stockholders' Equity (Deficit)


From Inception
(August 17, 2006) to March 31, 2010




Common Stock
                        
                        
                        Additional
                          Paid
      In
                        
                        
                        Deficit
                          Accumulated
                          during the
                          DevelopmentShares
                        
                        
                        Amount
                        
                        
                        Capital
                        
                        
                        Stage
                        
                        
                        TotalBalance,
      August 17, 2006
                        
                        
                        -
                        
                        
                        $
                        -
                        
                        
                        $
                        -
                        
                        
                        $
                        -
                        
                        
                        $
                        -Common
      shares issued for cash, $0.46 per share between August 2006 and March
      2007
                        
                        
                        156,522
                        
                        
                        
                        157
                        
                        
                        
                        71,843
                        
                        
                        
                        -
                        
                        
                        
                        72,000Net
      loss for the period from inception on August 17, 2006 through March 31,
      2007
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        (2,640
                        )
                        
                        
                        (2,640
                        )Balance,
      March 31, 2007
                        
                        
                        156,522
                        
                        
                        
                        157
                        
                        
                        
                        71,843
                        
                        
                        
                        (2,640
                        )
                        
                        
                        69,360Net
      loss for the year ended March 31, 2008
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        (20,744
                        )
                        
                        
                        (20,744
                        )Balance,
      March 31, 2008
                        
                        
                        156,522
                        
                        
                        
                        157
                        
                        
                        
                        71,843
                        
                        
                        
                        (23,384
                        )
                        
                        
                        48,616Common
      shares issued for services, $4.6 per share on June 12,
2008
                        
                        
                        1,522
                        
                        
                        
                        2
                        
                        
                        
                        6,998
                        
                        
                        
                        -
                        
                        
                        
                        7,000Common
      shares issued for cash, $4.6 per share on June 30, 2008
                        
                        
                        22,266
                        
                        
                        
                        22
                        
                        
                        
                        102,403
                        
                        
                        
                        -
                        
                        
                        
                        102,425Common
      shares issued for services at $11.5 per share on January 1,
      2009
                        
                        
                        21,739
                        
                        
                        
                        22
                        
                        
                        
                        249,978
                        
                        
                        
                        -
                        
                        
                        
                        250,000Common
      shares repurchased and retired at $0.046 per share on March 11,
      2009
                        
                        
                        (152,174
                        )
                        
                        
                        (152
                        )
                        
                        
                        (6,848
                        )
                        
                        
                        -
                        
                        
                        
                        (7,000
                        )Additional
      shares issued in the 1 for 46 share reverse stock split due to rounding up
      of fractional shares
                        
                        
                        21
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -Net
      loss for the year ended March 31, 2009
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        (349,607
                        )
                        
                        
                        (349,607
                        )Balance,
      March 31, 2009 (Restated)
                        
                        
                        49,896
                        
                        
                        $
                        51
                        
                        
                        $
                        424,374
                        
                        
                        $
                        (372,991
                        )
                        
                        $
                        51,434Forgiveness
      of debt from related party
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        4,500
                        
                        
                        
                        
                        
                        
                        $
                        4,500Net
      loss for the year ended March 31, 2010
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        -
                        
                        
                        
                        (60,519
                        )
                        
                        
                        (60,519
                        )Ending
      Balance,  March 31, 2010
                        
                        
                        49,896
                        
                        
                        $
                        51
                        
                        
                        $
                        428,874
                        
                        
                        $
                        (433,510
                        )
                        
                        $
                        (4,585
                        )





The
accompanying notes are an integral part of these financial
statements.


5





China
Domestica Bio-technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Statements
of Cash Flows


For
the Years Ended March 31, 2010 and 2009


and
from Inception (August 17, 2006) to March 31, 2010





From InceptionYear Ended March 31,
                          
                          
                          (August 17,
                            2006) to2010
                          
                          
                          2009
                          
                          
                          March 31, 2010(Restated)Cash
      Flows Provided By (Used In) Operating ActivitiesNet
      income (loss)
                          
                          $
                          (60,519
                          )
                          
                          $
                          (349,607
                          )
                          
                          $
                          (433,510
                          )Adjustments
      to reconcile net income (loss) to net cash provided from (used by)
      operating activities:Common
      stock issued for services
                          
                          
                          -
                          
                          
                          
                          257,000
                          
                          
                          
                          257,000Depreciation
      and amortization
                          
                          
                          1,664
                          
                          
                          
                          924
                          
                          
                          
                          2,936Impairment
      of fixed assets
                          
                          
                          -
                          
                          
                          
                          1,327
                          
                          
                          
                          1,327Loss
      on disposal of fixed assets
                          
                          
                          1,516
                          
                          
                          
                          -
                          
                          
                          
                          1,516Changes
      in operating assets and liabilities:Prepaid
      officer's salaries
                          
                          
                          37,500
                          
                          
                          
                          (37,500
                          )
                          
                          
                          -Increase
      (decrease) in accounts payable
                          
                          
                          (1,773
                          )
                          
                          
                          1,643
                          
                          
                          
                          200Net
      cash provided by (used in) operating activities
                          
                          
                          (21,612
                          )
                          
                          
                          (126,213
                          )
                          
                          
                          (170,531
                          )Cash
      Flows Provided By (Used In) Investing ActivitiesPurchase
      of fixed assets
                          
                          
                          -
                          
                          
                          
                          (5,680
                          )
                          
                          
                          (7,179
                          )Sale
      of fixed assets
                          
                          
                          1,400
                          
                          
                          
                          -
                          
                          
                          
                          1,400Net
      cash provided by (used in) investing activities
                          
                          
                          1,400
                          
                          
                          
                          (5,680
                          )
                          
                          
                          (5,779
                          )Cash
      Flows Provided By (Used In) Financing ActivitiesProceeds
      from loan by related party
                          
                          
                          9,100
                          
                          
                          
                          -
                          
                          
                          
                          9,100Common
      stock purchased and retired
                          
                          
                          -
                          
                          
                          
                          (7,000
                          )
                          
                          
                          (7,000
                          )Issuance
      of common stock for cash
                          
                          
                          -
                          
                          
                          
                          102,425
                          
                          
                          
                          174,425Net
      cash provided by (used in) financing activities
                          
                          
                          9,100
                          
                          
                          
                          95,425
                          
                          
                          
                          176,525Net
      increase (decrease) in cash and cash equivalents
                          
                          
                          (11,112
                          )
                          
                          
                          (36,468
                          )
                          
                          
                          215Cash
      and cash equivalents, beginning of period
                          
                          
                          11,327
                          
                          
                          
                          47,795
                          
                          
                          
                          -Cash
      and cash equivalents, end of period
                          
                          $
                          215
                          
                          
                          $
                          11,327
                          
                          
                          $
                          215Supplemental
      disclosure of Cash Flow InformationInterest
      paid
                          
                          $
                          -
                          
                          
                          $
                          -
                          
                          
                          $
                          -Income
      taxes paid
                          
                          $
                          -
                          
                          
                          $
                          -
                          
                          
                          $
                          -Schedule
      of Non Cash investing and financing activitiesCommon
      stock issued for services
                          
                          $
                          -
                          
                          
                          $
                          257,000
                          
                          
                          $
                          257,000Impairment
      of fixed assets
                          
                          $
                          -
                          
                          
                          $
                          1,327
                          
                          
                          $
                          1,327Loss
      on disposal of fixed assets
                          
                          $
                          1,516
                          
                          
                          $
                          -
                          
                          
                          $
                          1,516Forgiveness
      of debt from related party
                          
                          $
                          4,500
                          
                          
                          $
                          -
                          
                          
                          $
                          4,500





The
accompanying notes are an integral part of these financial
statements.


6





China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009








1.
            Business
      Organization




China
Domestica Bio-technology Holdings, Inc. was incorporated in the State of Nevada
on August 17, 2006 under the name Cienega Creek Holdings, Inc.  The
Company, a corporation (the Company) was organized under laws of the State of
Nevada on August 17, 2006.  On June 29, 2010, the Company changed its
name to China Domestica Bio-technology Holdings, Inc.  The Company’s
fiscal year end is March 31st.  The Company was previously engaged in
the computer software business. The Company has not realized revenues from
operations as of March 31, 2010 and accordingly is classified as a development
stage company.  The company is currently in the development stage and
has limited assets and no revenue. In accordance with FASB ASC 915, it is
considered a Development Stage Company.





Accounting
Basis


These
financial statements have been prepared on the accrual basis of accounting
following generally accepted accounting principles in the United States of
America consistently applied.





2.
            Summary
      of Significant Accounting Policies





Cash
and Cash Equivalents


For
Statement of Cash Flows purposes, the Company considers all cash on hand and in
banks, certificates of deposit and other highly-liquid investments with
maturities of three months or less, when purchased, to be cash and cash
equivalents.





Property
and Equipment


Property
and equipment are stated at cost. Depreciation has been calculated over the
estimated useful lives of the assets using the straight line
method.  The cost of maintenance and repairs is expensed as
incurred.




Impairment
of Long-Lived Assets


The
Company continually monitors events and changes in circumstances that could
indicate carrying amounts of long-lived assets may not be recoverable. When such
events or changes in circumstances are present, the Company assesses the
recoverability of long-lived assets by determining whether the carrying value of
such assets will be recovered through undiscounted expected future cash flows.
If the total of the future cash flows is less than the carrying amount of those
assets, the Company recognizes an impairment loss based on the excess of the
carrying amount over the fair value of the assets. Assets to be disposed of are
reported at the lower of the carrying amount or the fair value less costs to
sell.





Advertising
Costs


The
Company's policy regarding advertising is to expense advertising when incurred.
The Company has incurred no advertising expenses during the year ended March 31,
2010 and $1,856 during the year ended March 31, 2009.


7


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





2.
            Summary
      of Significant Accounting Policies
(cont.)




Revenue
Recognition
 Presently,
the Company is in the development stage and as such, has no
revenues.  Upon emerging from the development stage the Company will
adopt a policy of recognizing revenue when a definitive agreement with a
determinable price exists, product delivery and/or invoicing (in each case where
there is reasonable assurance of meeting customer-specified criteria) has
occurred, and the collectibility of the invoice is reasonably
assured.




Income
Taxes


The
Company uses the asset and liability method of accounting for income taxes. At
March 31, 2010, respectively, the deferred tax asset and deferred tax liability
accounts, as recorded when material to the financial statements, are entirely
the result of temporary differences.  Temporary differences represent
differences in the recognition of assets and liabilities for tax and financial
reporting purposes, primarily accumulated depreciation and
amortization.





As of
March 31, 2010, the deferred tax asset related to the Company's net operating
loss carryforward is fully reserved.  Due to the provisions of
Internal Revenue Code Section 338, the Company may have no net operating loss
carryforwards available to offset financial statement or tax return taxable
income in future periods as a result of a change in control involving 50
percentage points or more of the issued and outstanding securities of the
Company.





Dividends


The
Company is a Development Stage Company and has not yet adopted a policy
regarding the payment of dividends.




8


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





2.
            Summary
      of Significant Accounting Policies
(Cont.)




Foreign
Currency Translation


The
financial statements are presented in United States Dollars.  During
the fiscal year ended, March 31, 2010, the Company was a United States Company
and accounted for in US Dollars.Effective with the acquisition of the
Company on April 26, 2010, in conjunction with the Common Stock Purchase
Agreement, the Company will be changing its’ functional currency to
the Chinese Renminbi (RMB) as the Company will be domiciled in the People’s
Republic of China (PRC).  This change in functional currency results in a
change in accounting principle and pursuant to current accounting literature
(ASC 250) changes should be accounted for retrospectively to all prior periods,
unless it is impractical to do so.  It was determined impracticable to
determine the cumulative effect if this change in accounting principle and the
retroactive application of this change to prior years, because the Company’s
accounting records do not provide sufficient information to apply this change in
functional currency.  As a result, this change will be applied
prospectively to the fiscal year ended, March 31, 2011.




In
accordance with FASB ASC 830, “Foreign Currency Translation”, foreign
denominated monetary assets and liabilities are translated into their United
States dollar equivalents using foreign exchange rates which prevailed at the
balance sheet date.  Non monetary assets are translated at the
exchange rates prevailing at the transaction date.  Revenue and
expenses are translated at average rates of exchange during the
year.  Gains or losses resulting from foreign currency transactions
are included in results of operations.





Earnings
(Loss) per Share


Basic
earnings (loss) per share is computed by dividing the net income (loss)
available to common shareholders by the weighted-average number of common shares
outstanding during the respective  period presented in our
accompanying financial statements.





Fully
diluted earnings (loss) per share is computed similar to basic income (loss) per
share except that the denominator is increased to include the number of common
stock equivalents (primarily outstanding options and warrants).





Common
stock equivalents represent the dilutive effect of the assumed exercise of
outstanding stock options and warrants, using the treasury stock method, at
either the beginning of the respective period presented or the date of issuance,
whichever is later, and only if the common stock equivalents are considered
dilutive based upon the Company’s net income (loss) position at the calculation
date.





As of
March 31, 2010, the Company’s has no issued and outstanding warrants or
options.


9


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





2.
            Summary
      of Significant Accounting Policies
(Cont.)




Use
of Estimates


The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.





Recent
Accounting Pronouncements


The
Company’s Management has evaluated recently issued accounting standards through
the filing date of these financial statements and believes that the recently
issued accounting standards will not have a material impact on the Company’s
financial position, operations, or cash flows.


10


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009








3.
            Restatement
      of Financial Statements




On
September 29, 2009, the Company discovered a material error in its accounting
that resulted in a misstatement of the financial statements for the fiscal year
ended March 31, 2009. The Company failed to record a prepaid expense for officer
salaries resulting in an understatement of current assets and an overstatement
of operating expenses of $37,500. The Company revalued shares issued for
services increasing professional fees and Additional Paid-in Capital by
$249,000. The Company also has corrected several smaller errors including
certain unrecorded liabilities, property and equipment, and accounts payable. In
the year ended March 31, 2009 these errors resulted in the understatement of
property and equipment by $960, an understatement of total liabilities by $1,973
and understatement of net loss by $1,013. Below are presented summaries of the
difference between the original and restated Balance Sheets for the year ended
March 31, 2009 and Statements of Operations and Statements of Cash Flows for the
year ended March 31, 2009.




BALANCE
SHEET




ASSETS




March 31,
                    
                    
                    March 31,2009
                    
                    
                    2009(Original)
                    
                    
                    (Restated)Current
      AssetsCash
                    
                    $
                    11,321
                    
                    
                    $
                    11,327Prepaid
      Officer Salary
                    
                    
                    -
                    
                    
                    
                    37,500Total
      Current Assets
                    
                    
                    11,321
                    
                    
                    
                    48,827Property
      and Equipment, net
                    
                    
                    3,620
                    
                    
                    
                    4,580Total
      Assets
                    
                    $
                    14,941
                    
                    
                    $
                    53,407




11


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009








3.
            Restatement
      of Financial Statements (Cont.)




LIABILITIES
AND STOCKHOLDERS' EQUITY





March 31,
                  
                  
                  March 31,2009
                  
                  
                  2009(Original)
                  
                  
                  (Restated)Current
      LiabilitiesAccounts
      payable
                  
                  $
                  -
                  
                  
                  $
                  1,973Related
      Party Payable
                  
                  
                  -
                  
                  
                  
                  -Total
      Current Liabilities
                  
                  
                  -
                  
                  
                  
                  1,973Stockholders'
      EquityCommon
      stock: $0.001 par value, 75,000,000 shares authorized, 2,294,250 issued
      and outstanding
                  
                  
                  2,294
                  
                  
                  
                  51Additional
      paid in capital
                  
                  
                  173,131
                  
                  
                  
                  424,374Deficit
      accumulated during the development stage
                  
                  
                  ( 160,484
                  )
                  
                  
                  ( 372,991
                  )Total
      Stockholders' Equity
                  
                  
                  14,941
                  
                  
                  
                  51,434Total
      Liabilities and Stockholders' Equity
                  
                  $
                  14,941
                  
                  
                  $
                  53,407





STATEMENT
OF OPERATIONS





March
      31,2009
                    
                    
                    2009(Original)
                    
                    
                    (Restated)REVENUES
                    
                    $
                    -
                    
                    
                    $
                    -OPERATING
      EXPENSESOfficer
      Salaries
                    
                    
                    -
                    
                    
                    
                    12,500Professional
      fees
                    
                    
                    -
                    
                    
                    
                    17,162Professional
      fees-related party
                    
                    
                    -
                    
                    
                    
                    304,250Depreciation
      expense
                    
                    
                    402
                    
                    
                    
                    924General
      and administrative
                    
                    
                    137,289
                    
                    
                    
                    13,561Total
      Operating Expenses
                    
                    
                    137,691
                    
                    
                    
                    348,397LOSS
      FROM OPERATIONS
                    
                    
                    (137,691
                    )
                    
                    
                    (348,397
                    )




12


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009








3.
            Restatement
      of Financial Statements (Cont.)




OTHER
      EXPENSESInterest
      income
                  
                  
                  111
                  
                  
                  
                  117Impairment
      expense
                  
                  
                  -
                  
                  
                  
                  (1,327
                  )Total
      Other Income  (Expense)
                  
                  
                  111
                  
                  
                  
                  (1,210
                  )NET
      LOSS BEFORE INCOME TAXES
                  
                  
                  (137,691
                  )
                  
                  
                  (349,607
                  )INCOME
      TAX EXPENSE
                  
                  
                  -
                  
                  
                  
                  -NET
      LOSS
                  
                  $
                  (137,580
                  )
                  
                  $
                  (349,607
                  )BASIC
      LOSS PER SHARE
                  
                  $
                  (0.80
                  )
                  
                  $
                  (2.04
                  )WEIGHTED
      AVERAGE NUMBER  OF SHARES OUTSTANDING  ( After effect
      of 1 for 46 share reverse split)
                  
                  
                  171,417
                  
                  
                  
                  171,124




STATEMENT
OF  CASH FLOWS


For the year endedMarch
      31,2009
                  
                  
                  2009(Original)
                  
                  
                  (Restated)OPERATING
      ACTIVITIESNet
      loss
                  
                  $
                  (130,580
                  )
                  
                  $
                  (349,607
                  )Adjustments
      to Reconcile Net Loss to Net Cash Used by Operating
      Activities:Common
      stock issued for services
                  
                  
                  8,000
                  
                  
                  
                  257,000Prepaid
      officer salaries
                  
                  
                  -
                  
                  
                  
                  (
      37,500
                  )Depreciation
      and amortization
                  
                  
                  402
                  
                  
                  
                  924Impairment
      of fixed assets
                  
                  
                  -
                  
                  
                  
                  1,327Changes
      in operating assets and liabilities:Change
      in accounts payable
                  
                  
                  -
                  
                  
                  
                  1,643Net
      Cash Used in Operating Activities
                  
                  
                  (129,178
                  )
                  
                  
                  (126,213
                  )




13


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009







3.
            Restatement
      of Financial Statements (Cont.)




INVESTING
      ACTIVITIESPurchase
      of fixed assets
                  
                  
                  ( 2,721
                  )
                  
                  
                  (5,680
                  )Sale
      of fixed assets
                  
                  
                  -
                  
                  
                  
                  -Net
      Cash Used in Investing Activities
                  
                  
                  (2,721
                  )
                  
                  
                  (5,680
                  )FINANCING
      ACTIVITIESRelated
      party payable
                  
                  
                  -
                  
                  
                  
                  -Common
      stock repurchased and retired
                  
                  
                  ( 7,000
                  )
                  
                  
                  ( 7,000
                  )Issuance
      of common stock for cash
                  
                  
                  102,425
                  
                  
                  
                  102,425Net
      Cash Provided by Financing Activities
                  
                  
                  95,425
                  
                  
                  
                  95,425NET
      INCREASE(DECREASE) IN CASH
                  
                  
                  (
      36,474
                  )
                  
                  
                  (
      36,468
                  )CASH
      AT BEGINNING OF PERIOD
                  
                  
                  47,795
                  
                  
                  
                  47,795CASH
      AT END OF PERIOD
                  
                  $
                  11,321
                  
                  
                  $
                  11,321Schedule
      of noncash investing and financing activitiesCommon
      stock issued for services
                  
                  
                  
                  
                  
                  $
                  257,000Impairment
      of Fixed Assets
                  
                  
                  
                  
                  
                  $
                  1,327





4.
            Going
      Concern





The
accompanying financial statements have been prepared assuming the Company will
continue as a going concern, which contemplates the realization of assets and
the liquidation of liabilities in the normal course of
business.  However, the Company has incurred significant losses and is
dependent on obtaining adequate capital to fund operating losses until it
becomes profitable. If the Company is unable to obtain the necessary funding it
could cease operations as a new enterprise.





Management
anticipates that the Company will be dependent, for the near future, on
additional investment capital to fund operating expenses. The Company intends to
position itself so that it may be able to raise additional funds through the
capital markets. In light of management's efforts, there are no assurances that
the Company will be successful in this or any of its endeavors or become
financially viable and continue as a going concern. This raises substantial
doubt about the Company’s ability to continue as a going
concern.  These financial statements do not include any adjustments
that might result from this uncertainty.




14


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





5.
            Property
      And Equipment





Property
and equipment are stated at cost.  Depreciation expense for the years
ended March 31, 2010 and 2009 amounted to $1,664 and $924,
respectively.  Gains from losses on sales and disposals are included
in the statements of operations.  Maintenance and repairs are charged
to expense as incurred.





At the
close of the fiscal year ended March 31, 2009 the Company’s management impaired
the value of a trailer and the land held on the company books due to the fact
that the Company sold these pieces of property and equipment subsequent to the
balance sheet date but prior to the release of the financial statements for a
price lower than the carrying value.  The Company impaired these two
items at the close of the fiscal year ended March 31, 2009 by a total of $1,327
to more accurately reflect the market value at year end.  The remaining
laptop computer and marketing materials having a Net Book Value of $1,516 were
donated to charity subsequent to the balance sheet date.  Accordingly, the
Company's management impaired the value of these items on the Company's books at
March 31, 2010 by a total of $1,516 to accurately reflect the market value at
year end.









6.
              Capital
      Stock




On August
8, 2006, the Company received $3,000 from its founder for 6,522 shares of
its common stock. On March 20, 2007, the Company completed an unregistered
private offering under the Securities Act of 1933, as amended, relying upon the
exemption from registration afforded by Rule 504 of Regulation D promulgated
there under. The Company issued 150,000 shares of its common stock at a price of
$0.46 per share for $69,000 in cash.




On June
12, 2008, 1,522 shares of common stock were issued for service valued at
$7,000, on June 30, 2008, the Company issued 22,266 shares of its common
stock for  $102,425 and on January 1, 2009 the Company issued an
additional 21,739 shares of common stock for services to its President for
having met certain Company milestones valued at $250,000. On March 11, 2009, the
Company repurchased and retired 152,174 shares of its common stock for
$7,000.  The shares were purchased from the estate of one of the
Company's deceased directors.




On June
29, 2010, the Company effected a one for forty six (1:46) reverse stock
split of the outstanding shares of Common Stock.  The reverse stock split
reduced the number of issued and outstanding shares of common stock of the
Company from 2,294,250 shares outstanding prior to the reverse stock split to
49,896 shares outstanding after the reverse stock split.  The Company
issued an additional 21 shares of common stock in connection with the reverse
stock split due to the rounding up of fractional shares.  This reverse
stock split became effective June 29, 2010. These financial
statements show the retroactive effect of this reverse stock
split.





At March
31, 2010, there were no outstanding stock options or warrants.





7.
            Income
      Taxes




The
Company provides for income taxes under Statement of Financial Accounting
Standards No. 109, Accounting for Income Taxes. SFAS No. 109 requires the use of
an asset and liability approach in accounting for income taxes. Deferred tax
assets and liabilities are recorded based on the differences between the
financial statement and tax bases of assets and liabilities and the tax rates in
effect when these differences are expected to reverse. SFAS No. 109 requires the
reduction of deferred tax assets by a valuation allowance if, based on the
weight of available evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized.


15


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





7.
            Income
      Taxes (Cont.)




The
provision for income taxes differs from the amounts which would be provided by
applying the statutory federal income tax rate of 39% to the net loss before
provision for income taxes for the following reasons:





March
      31,2010
                            
                            
                            2009Income
      tax expense at statutory rate
                            
                            $
                            (23,602
                            )
                            
                            $
                            (136,347
                            )Valuation
      allowance
                            
                            
                            23,602
                            
                            
                            
                            136,347Income
      tax expense per books
                            
                            $
                            -
                            
                            
                            $
                            -




Net
deferred tax assets consist of the following components as of March
31:





2010
                          
                          
                          2009Net
      Operating Loss Carryover
                          
                          $
                          (169,069
                          )
                          
                          $
                          (
      145,466
                          )Valuation
      allowance
                          
                          
                          169,069
                          
                          
                          
                          145,466Net
      deferred tax asset
                          
                          $
                          -
                          
                          
                          $
                          -




The
Company has a net operating loss carryover of $433,510 as of March 31, 2010
which expires in 2026. Due to the change in ownership provisions of the Tax
Reform Act of 1986, net operating loss carry forwards for federal income tax
reporting purposes are subject to annual limitations. Should a change in
ownership occur net operating loss carry forwards may be limited as to use in
future years.





The
Company has net operating loss carryforwards that were derived solely from
operating losses from prior years.  These amounts can be carried
forward to offset future taxable income for a period of 20 years for each tax
year’s loss.  No provision was made for federal income taxes as the
Company has significant net operating losses.





At March
31, 2010 and 2009, the Company has established a valuation allowance equal to
the deferred tax assets as there is no assurance that the Company will generate
future taxable income to utilize these assets.





Due to
the provisions of Internal Revenue Code Section 338, the Company may have no net
operating loss carryforwards available to offset financial statement or tax
return taxable income in future periods as a result of a change in control
involving 50 percentage points or more of the issued and outstanding securities
of the Company.


16


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





8.
            Related
      Party Transactions





As of
March 31, 2010 and 2009, the Company owed $4,600 and $0, respectively, to
its former President and CEO.  This note payable is noninterest
bearing, unsecured and due on demand.





On
December 4, 2008 the Company entered into an employment agreement with its
President and CEO for $50,000 annual salary beginning on January 1, 2009 and
terminating on December 31, 2013.  On January 1, 2010 this agreement
was terminated and no further salary is owed or to be accrued.




9.
            Subsequent
      Events





On March
16, 2010, Cienega Creek Holdings, Inc., (the “Company”) entered into a material
definitive agreement with Belmont Partners, LLC by which Belmont acquired one
million two hundred ninety nine thousand (1,299,000) shares of the Company’s
common stock. The transaction closed on March 18, 2010. Following the
transaction, Belmont Partners, LLC controlled approximately 56.61% of the
Company’s outstanding capital stock.





On April
26, 2010, Cienega Creek Holdings, Inc. (the “Company”) entered into a Common
Stock Purchase Agreement (the “Purchase Agreement”) by and among China Sheng
Yong Bio-pharmaceutical Holding Company Limited, a British Virgin Islands
limited company (the “Buyer”), Belmont Partners, LLC, a Virginia limited
liability company (the “Seller”), and the Company.  Pursuant to the
terms of the Purchase Agreement, on April 26, 2010 (the “Closing Date”), the
Buyer acquired from the Seller 1,299,000 shares (the “Purchased Stock”), or
approximately 56.62%, of the issued and outstanding common stock of the
Company.  In consideration for the sale of the Purchased Stock, the
Buyer paid the Seller $280,000 and the Company agreed to issue to the Seller
shares of its common stock (the “Issued Stock”) such that the Seller will own 5%
of the issued and outstanding capital stock of the Company after the closing of
a merger transaction with an as of yet unidentified target corporation
contemplated by the Purchase Agreement.  Pursuant to the terms of the
Purchase Agreement, the then current officer and director of the Company
resigned on the Closing Date and Qingyu Meng was named President and Director of
the Company and Yung Kong Chin was named Secretary and Director of the
Company.  Qingyu Meng  is a director and President of the
Buyer and Yung Kong Chin is a director and Secretary of the
Buyer.  The resignation of the current director and the naming of Yung
Kong Chin and Qingyu Meng as directors will take effect on the tenth day
following the mailing by the Company of an information statement that complies
with the requirements of Section 14f-1 of the Securities Exchange Act of
1934.  Joseph J. Meuse, the former President and a current director of
the Company, is a managing member of the
Seller.


17


China
Domestica Bio-Technology Holdings, Inc.


(formerly
Cienega Creek Holdings, Inc.)


(A
Development Stage Company)


Notes
to Financial Statements


March 31, 2010 & 2009





9.
            Subsequent
      Events (Cont.)




On June 29, 2010 the
company amended its Articles of Incorporation as follows:





·
            Changed
      the name of the Corporation to “China Domestica Bio-technology Holdings,
      Inc.”.




·
            Authorized
      up to 10,000,000 shares of “blank check” preferred stock to be designated
      in such series and with such preferences as the Board of Directors shall
      determine.




·
              To
      effect a one for forty-six (1:46) reverse stock split of the outstanding
      shares of Common Stock. This reverse stock split became effective June 29,
      2010. These financial statements give retroactive effect to the
      reverse stock split.




In
September 2010, Michael Klinicki, our former CEO and President, agreed to waive
repayment of $4,600 owed to him by the Company.


18